Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

The 8p11 myeloproliferative syndrome is a rare, aggressive myeloproliferative neoplasm characterized by constitutively active FGFR1 fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation. Although FGFR1 inhibitors have shown in vitro activity again...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Chase, Andrew, Bryant, Catherine, Score, Joannah, Cross, Nicholas C.P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2013
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3533670/
https://ncbi.nlm.nih.gov/pubmed/22875613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.066407
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg